Ubiquisys, the developer of 3G femtocells, today announced it has completed a $9M funding round led by 5 Continents Consulting Group (5CCG), with participation from new investorĀ Enterprise Development Co. and existing investors Advent Venture Partners, Accel Partners and Atlas Venture.
Ubiquisys says the capital will be used to accelerate the company’s programme to meet ‘significant demand’ for its femtocell technology, including new market segments such as indoor hot-spots, metro and rural deployments. The strategic investors bring significant expertise which will support the next generation of Ubiquisys products and its expansion into new markets.
In the past twelve months Ubiquisys says it has met a number of strategic milestones, including:
– SFR in France and SoftBank in Japan have successfully launched with Ubiquisys femtocells, driving strong revenue growth.
– SoftBank is offering its femtocells for free, driving massive consumer demand.
– Exploiting its extensive IPR to develop the full range of small cells: residential, enterprise, rural and metro.
– Its Femto-Engine software system has enabled the only femtocell with a wholesale price below $100.
“Ubiquisys is in a great position right now as we believe that the dynamic growth of the global Femto market is just starting-up. Ubiquisys has a sustainable technology advantage, its products have been tested and launched by multiple operators across the world, and it has started to deliver serious volumes,” said Michael BornhƤusser, Founder and Managing Partner of 5CCG. “I’m very excited to be getting involved in further accelerating the company’s growth and supporting the company on the board of directors.”
“The femtocell market is ramping faster than we envisaged, and the advent of the free model, pioneered by SoftBank and enabled by Ubiquisys, will only increase that momentum,” said Chris Gilbert, CEO Ubiquisys. “We are delighted to add the high-calibre support of 5CCG and Yasuda to our strong investor base as we embark on the next phase of our growth strategy.”